A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic of SYH9017 in Chinese Participants With Overweight and Obesity Following Single and Multiple Doses

This is a randomized, double-blind, single-center, dose-escalation, single ascending dose and multiple ascending dose study of SYH9017 in Chinese participants with overweight and obesity.

开始日期2025-02-27

申办/合作机构

石药集团百克（山东）生物制药股份有限公司

CTR20250475

/ Recruiting临床1期

评价SYH9017注射液在中国超重与肥胖参与者中单、多次给药的安全性、耐受性和药代动力学特征的Ⅰ期临床试验

第一阶段（SAD）主要目的：评价SYH9017注射液单次皮下注射给药在中国超重与肥胖参与者中的安全性、耐受性次要目的：评价SYH9017注射液单次皮下注射给药在中国超重与肥胖参与者中的PK特征；评价SYH9017注射液单次给药在中国超重与肥胖参与者中的免疫原性；评价SYH9017注射液单次给药在中国超重与肥胖参与者中的PD特征第二阶段（MAD）主要目的：评价SYH9017注射液多次皮下注射给药在中国超重与肥胖参与者中的安全性、耐受性次要目的：评价SYH9017注射液多次皮下注射给药在中国超重与肥胖参与者中的PK特征；评价SYH9017注射液多次给药在中国超重与肥胖参与者中的免疫原性；评价SYH9017注射液多次给药在中国超重与肥胖参与者中PD特征；评价SYH9017注射液和司美格鲁肽注射液（诺和盈®）的PK特征、PD特征、安全性比对

开始日期2025-02-24

申办/合作机构

石药集团百克（山东）生物制药股份有限公司

[+1]

NCT06604624

/ Active, not recruiting临床3期

To Evaluate a Multicenter, Randomized, Open, Positive Parallel Controlled Phase III Clinical Trial of Semaglutide Injection (HD1916) in the Treatment of Obesity

This is a multicenter, randomized, open, positive parallel controlled phase III clinical trial to compare the efficacy and safety of once-weekly HD1916 and semaglutide injection and to evaluate immunogenicity in obese non-diabetic adults.

开始日期2024-09-20

申办/合作机构

石药集团百克（山东）生物制药股份有限公司

100 项与司美格鲁肽（石药集团中奇制药）相关的临床结果

登录后查看更多信息

100 项与司美格鲁肽（石药集团中奇制药）相关的转化医学

登录后查看更多信息

100 项与司美格鲁肽（石药集团中奇制药）相关的专利（医药）

登录后查看更多信息

417

项与司美格鲁肽（石药集团中奇制药）相关的文献（医药）

2025-06-01·JOURNAL OF CONTROLLED RELEASE

Enzymatic absorption promoters for non-invasive peptide delivery

Article

作者: Cerrejon, David Klein ; Gao, Daniel ; Burger, Michael ; Heussi, Miguel ; Steiger, Marilena Bohley ; Leroux, Jean-Christophe ; Merkl, Padryk ; Steinauer, Angela ; Krupke, Hanna ; Klipp, Alexander ; Martin-Olmos, Cristina

Peptide drugs offer considerable potential for treating a diverse range of diseases. Yet, their clinical application is generally restricted to injectable therapies. The main challenge hindering their broader use through globally accessible, patient-friendly, and non-invasive delivery routes such as oral or buccal, lies in their poor ability to cross biological barriers effectively. Here, we demonstrate that enzymes can be harnessed to transiently reduce these barriers and improve absorption. As a proof of concept, we employ a mucin-specific protease (mucinase) and a phospholipase to increase mucus diffusivity and epithelial cell membrane permeability, respectively. In a canine model, we show that enteric capsules containing both enzymes, and the peptide drug desmopressin achieved a relative bioavailability of 155 % compared to the drug alone. Additionally, a buccal patch loaded with phospholipase and semaglutide displayed a 5-fold higher bioavailability and lower variability (71.5 % reduction in the coefficient of variation) compared to the commercially available oral tablet. These results suggest that enzymatic modulation of biological barriers holds promise as a strategy to improve non-invasive delivery of peptides and potentially other macromolecular drugs.

2025-05-01·Endocrinology, diabetes & metabolism

Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta‐Analysis of Direct Comparative Studies

Review

作者: Syed, Burhaan ; How‐Volkman, Christiane ; Truong, Alina ; Akhtar, Muzammil ; Frezza, Eldo ; Razick, Adam ; Nadora, Denise ; Puglisi, Jose ; Wen, Jimmy ; Bernstein, Ethan

ABSTRACT:

Introduction:

Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have emerged as an efficacious treatment for type 2 diabetes mellitus (T2DM) and have demonstrated substantial weight loss effects. This systematic review compares two prevalent GLP‐1RAs, tirzepatide and semaglutide, with their weight loss effects and rates of adverse events (AEs).

Methods:

Following the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA), a systematic search was performed in PubMed, Embase and Cochrane Library for direct comparative studies between tirzepatide and semaglutide. A meta‐analysis was conducted via a random‐effects model to analyse the differences in weight loss outcomes between study cohorts.

Results:

Four studies, with 28,827 patients (14,870 tirzepatide/13,928 semaglutide), mean age of 55.7 years (52.0 to 63.7) and mean follow‐up of 35.9 weeks (23.6 to 44.6), were included in this study. Mean weight change across four studies for tirzepatide and semaglutide was −11.4% (−15.3% to −8.27%) and −7.3% (−8.3% to −6.08%), respectively. The meta‐analysis supports these findings with a mean difference of −4.84 kg (95% CI: −6.21 to −3.47), favouring tirzepatide. The most common AEs were minor and moderate‐severity gastrointestinal (GI) AEs.

Conclusion:

Current literature supports tirzepatide demonstrating a higher impact on weight loss than semaglutide, with both demonstrating high rates of minimal‐ to moderate‐severity AEs. Further research with comparative head‐to‐head trials will better elucidate these weight loss effects and safety profiles.

2025-05-01·Biomedical Materials

Chitosan hydrochloride coated and nonionic surfactant modified niosomes: a better way for oral administration of semaglutide

Article

作者: Bai, Lu ; Xu, Minhao ; Wang, Ben ; Kuang, Meiyan ; Liu, Xingyou ; Luo, Yi ; Sun, Meng ; Tang, Yaqin ; Su, Zhengxing ; Yan, Xinlei ; Xie, Jing ; Wang, Yu ; Guo, Yue

Abstract:

Diabetes is now a global chronic disease, with the number of people with diabetes expected to reach 643 million by the end of 2030. Semaglutide, a human glucagon-like peptide-1 (GLP-1) analogue with 94% similarity to human GLP-1, can promote insulin secretion and repress glucagon secretion in a glucose concentration-dependent manner, resulting in substantial improvement of blood glucose levels and reducing the risk of hypoglycemia in patients with type 2 diabetes. To improve the absorption efficiency of semaglutide in oral delivery, we developed chitosan hydrochloride-coated and nonionic surfactant-modified niosomes (CS.HCL-NSPEs-NIO) as a new way to encapsulate it. The results showed that CS.HCL-NSPEs-NIO could efficiently penetrate the cell junctions in the intestinal endothelium and therefore promote drug absorbance. In addition, gastrointestinal distribution studies revealed that CS. HCL-NSPEs-NIO could stay in the intestine for more than 4 h, thus allowing for long-term glucose regulation. Effective reduction of blood glucose levels and weight loss were observed in db/db mice while no toxicity was detected in major organs. On the whole, our recommendation is that CS.HCL-NSPEs-NIO shows promise as an oral delivery tool for enhancing the hypoglycemic effects of semaglutide.

项与司美格鲁肽（石药集团中奇制药）相关的新闻（医药）

2025-04-21

·药时空

王明伟团队发表长篇综述：GLP-1R的结构药理学和信号转导机制

近日，上海交通大学医学院附属瑞金医院医药结构生物学转化研究中心周庆同副研究员和王明伟教授等受邀在Cell Press期刊Trends in Pharmacological Sciences（TiPS）在线发表了题为“Structural pharmacology and mechanisms of GLP-1R signaling”的长篇综述（封面文章），系统总结了GLP-1R结构药理学与信号转导机制的研究进展，揭示了其信号调控的多样性、精密性和复杂性，为新一代2型糖尿病与肥胖症治疗药物的研发奠定了理论基础。图1. 论文首页标题图2. TiPS封面胰高血糖素样肽-1受体（Glucagon-like peptide-1 receptor, GLP-1R）属于B1类G蛋白偶联受体，在血糖稳态调控中发挥关键作用，是肥胖症和2型糖尿病的治疗靶标1-4。GLP-1R由构象灵活的胞外域（Extracellular domain, ECD）和嵌在细胞膜上的跨膜域（Transmembrane domain, TMD）组成，两者共同参与内源性配体GLP-1的识别和跨膜信号转导。目前共有8款GLP-1R激动剂获批上市，其中7个为GLP-1R单靶点激动剂，尤以司美格鲁肽（Semaglutide）的市场表现为著；另外一个是替尔泊肽（Tirzepatide），为GLP-1R和葡萄糖依赖性促胰岛素释放多肽受体（Glucose-dependent insulinotropic polypeptide receptor, GIPR）双重激动剂2。这些获批药物在减重和降糖方面表现突出，但也存在多种副作用，最常见的是胃肠道反应（如恶心、呕吐和便秘）5，同时用药依从性和停药体重反弹问题亟待解决6。该综述系统回顾了GLP-1R激动剂作为降糖和减重药物的开发历程，详细列举了其三维结构解析的代表性成果，依次从内源性GLP-1的生理功能、GLP-1R激活机制、多肽与小分子激动剂迥异的受体识别模式和变构调节机理等方面揭示了GLP-1R信号调控的多样性、精密性与复杂性。该综述还展望了未来研究的重点，包括不同效应蛋白的识别特征、偏向性信号通路调节、停药体重反弹机制及个体化治疗策略等，指出对GLP-1R结构药理学与信号转导机制的深入理解有助于开发新一代单靶点和多重激动剂。处在非活化状态的GLP-1R，其ECD闭合并与TMD互锁；GLP-1结合后ECD竖直平行与GLP-1的羧基部分紧密互作，而GLP-1的氨基部分则插入TMD的正构位点，引起受体第六跨膜螺旋（Transmembrane helix 6, TM6）胞内侧向外移动，形成G蛋白结合口袋。G蛋白的偶联进一步推动TM6外移，破坏保守极性网络，增强GLP-1R与G蛋白之结合进而加速跨膜信号转导（图3）。图3. 处于不同活性状态下的GLP-1R结构特征。尽管多肽激动剂与GLP-1的序列差异显著，但具有相似的多肽—受体结合界面，特别是ECD和第一胞外环（Extracellular loop 1, ECL1）之构象高度一致（图4）。相比之下，GLP-1的代谢产物GLP-1(9-36)具有独特的结合位点和受体识别模式，与其弱激动活性相符。小分子激动剂则能诱导GLP-1R的ECD以不同方式弯曲靠近TMD，从而形成紧密的结合口袋以增大受体—配体互作面积。此外，正向变构调节剂通过稳定活性构象增强GLP-1(9–36)的弱效信号，而变构激动剂Compound 2则通过诱导ECD氨基端螺旋下移实现受体活化，为靶向GLP-1R的药物设计提供了新的思路（图5）。图4. 内源性GLP-1、多肽类激动剂与小分子激动剂识别和激活GLP-1R的结构特征。图5. GLP-1R的小分子变构调控剂的结合位点。GLP-1R结构药理学与信号转导机制研究已经取得了较多的进展，GLP-1R与Gs蛋白的偶联方式也获阐明，但和其他下游效应蛋白如Gq、Gi、GRK、β-arrestin等的分子互作仍待揭示。偏向激动剂（如ExP5）选择性激活Gs通路，展现出更优的降糖效果，但亦需优化以达到更强的治疗收益。动态结构研究技术（如时间分辨冷冻电镜、分子动力学模拟）将助力捕获受体激活过程中间态和解析变构信号转导网络，而原位断层成像有望揭示生理环境下GLP-1R复合物的结构。在临床层面，除了解决用药依从性和停药体重反弹问题外，通过结构药理学研究结合患者数据挖掘开发个性化疗法将克服因GLP-1R基因多态性导致的个体疗效差异。据悉，王明伟教授领导的团队长期从事GLP-1R激动剂的结构和功能研究，产生了一大批原创性成果，包括发现首个具有体内实验疗效的小分子GLP-1R激动剂（Boc5）7、解析胰高血糖素受体（Glucagon receptor, GCGR）跨膜区8和全长9、GLP-1R（跨膜区）10、GIPR（全长）11以及7个多重激动剂与GLP-1R、GIPR和/或GCGR形成的16个复合物2的三维结构等。上海交通大学医学院附属瑞金医院医药结构生物学转化研究中心课题组组长周庆同副研究员为该文的第一作者，王明伟教授为通讯作者。参与该文撰写的还有中国科学院上海药物研究所赵丰辉副研究员、杨德华研究员以及复旦大学基础医学院药理学系博士研究生张耀。文章链接： https://doi-org.libproxy1.nus.edu.sg/10.1016/j.tips.2025.03.003参考文献1. Graaf, C.; Donnelly, D.; Wootten, D.; Lau, J.; Sexton, P.M.; Miller, L.J.; Ahn, J.M.; Liao, J.; Fletcher, M.M.; Yang, D.; et al. Glucagon-like peptide-1 and its class B G protein-coupled receptors: a long march to therapeutic successes. Pharmacol Rev 2016, 68 (4), 954-1013.2. Zhou, Q.; Li, G.; Hang, K.; Li, J.; Yang, D.; Wang, M. W. Weight loss blockbuster development: a role for unimolecular polypharmacology. Annu Rev Pharmacol Toxicol 2025, 65 (1), 191-213.3. Drucker, D.J. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab 2022, 57, 101351.4. Wen, X.; Zhang, B.; Wu, B.; Xiao, H.; Li, Z.; Li, R.; Xu, X.; Li, T. Signaling pathways in obesity: mechanisms and therapeutic interventions. Signal Transduct Target Ther 2022, 7 (1), 298.5. Gorgojo-Martínez, J.J.; Mezquita-Raya, P.; Carretero-Gómez, J.; Castro, A.; Cebrián-Cuenca, A.; de Torres-Sánchez, A.; García-de-Lucas, M.D.; Núñez, J.; Obaya, J. C.; Soler, M.J.; et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med 2023, 12 (1), 145.6. Wilding, J.P.H.; Batterham, R.L.; Davies, M.; Van Gaal, L.F.; Kandler, K.; Konakli, K.; Lingvay, I.; McGowan, B. M.; Oral, T.K.; Rosenstock, J.; et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab 2022, 24 (8), 1553-1564.7. Chen, D.; Liao, J.; Li, N.; Zhou, C.; Liu, Q.; Wang, G.; Zhang, R.; Zhang, S.; Lin, L.; Chen, K.; et al. A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice. Proc Natl Acad Sci U S A 2007, 104 (3), 943-948.8. Siu, F.Y.; He, M.; de Graaf, C.; Han, G.W.; Yang, D.; Zhang, Z.; Zhou, C.; Xu, Q.; Wacker, D.; Joseph, J.S.; et al. Structure of the human glucagon class B G-protein-coupled receptor. Nature 2013, 499 (7459), 444-449.9. Zhang, H.; Qiao, A.; Yang, D.; Yang, L.; Dai, A.; de Graaf, C.; Reedtz-Runge, S.; Dharmarajan, V.; Zhang, H.; Han, G.W.; et al. Structure of the full-length glucagon class B G-protein-coupled receptor. Nature 2017, 546 (7657), 259-264.10. Song, G.; Yang, D.; Wang, Y.; de Graaf, C.; Zhou, Q.; Jiang, S.; Liu, K.; Cai, X.; Dai, A.; Lin, G.; et al. Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators. Nature 2017, 546 (7657), 312-315.11. Zhao, F.; Zhang, C.; Zhou, Q.; Hang, K.; Zou, X.; Chen, Y.; Wu, F.; Rao, Q.; Dai, A.; Yin, W. Structural insights into hormone recognition by the human glucose-dependent insulinotropic polypeptide receptor. Elife 2021, 10, e68719识别微信二维码，可添加药时空小编请注明：姓名+研究方向！

上市批准临床结果

2025-04-20

·药渡

礼来口服GLP-1药物III期临床成功，千亿市场格局生变

来源：药渡撰文：Pharmadeep 编辑：维他命全球糖尿病与肥胖症患者人数持续攀升，GLP-1（胰高血糖素样肽-1）受体激动剂作为近年来最受瞩目的药物类别，凭借显著的降糖与减重效果，已成为医药行业的黄金赛道。然而，现有主流GLP-1药物（如司美格鲁肽、替尔泊肽）均为注射剂型，患者依从性受限。2025年4月17日，礼来公司宣布其口服小分子GLP-1药物Orforglipron（奥格列龙）的III期临床试验（ACHIEVE-1）取得积极结果，标志着GLP-1疗法即将迈入“口服时代”。这一突破不仅为患者提供更便捷的治疗选择，更可能重塑全球糖尿病与肥胖药物市场的竞争格局。PART.01Orforglipron III期数据疗效与安全性迎双突破ACHIEVE-1研究纳入了559例饮食和运动控制不佳的2型糖尿病患者，随机接受Orforglipron（3mg、12mg、36mg）或安慰剂治疗40周。结果显示，Orforglipron在降糖与减重方面均展现出显著优势。表1. ACHIEVE试验相关数据，来源：礼来公众号在主要终点，36mg剂量组的糖化血红蛋白（A1C）平均降低1.5%（基线8.0%），显著优于安慰剂组的0.1%（p<0.001）。在关键次要终点，65%接受36mg剂量治疗的患者A1C降至≤6.5%（ADA定义的糖尿病阈值以下），糖尿病缓解率令人瞩目。在减重效果方面，36mg剂量组患者平均减重7.3kg（7.9%），且研究结束时尚未达到体重平台期，提示长期治疗可能实现更优效果。在安全性方面，Orforglipron的耐受性良好，主要不良反应为轻至中度胃肠道事件（如腹泻、恶心等），与现有GLP-1类药物的安全性特征一致。因不良事件导致的停药率较低（3mg组6%，12mg组4%，36mg组8%，安慰剂组为1%），且未发现肝脏毒性信号。此外，Orforglipron作为口服小分子药物，无需餐前注射或严格饮食控制，患者依从性显著提升。其药物设计通过非肽类结构绕过胃酸降解问题，生物利用度稳定，每日一次给药即可维持疗效，这一差异化优势使其在市场竞争中脱颖而出。PART.02口服剂型如何颠覆市场格局？现有GLP-1药物市场主要由注射剂型主导。例如，诺和诺德的司美格鲁肽2024年全球销售额将近300亿美元，但需每周皮下注射，部分患者因疼痛或操作不便而停药。礼来的替尔泊肽作为双靶点（GLP-1/GIP）药物，减重效果优于司美格鲁肽，但仍为注射剂型。相比之下，Orforglipron的口服剂型为患者提供了更便捷的选择，可覆盖对注射抵触的患者群体，潜在市场扩大30%以上。表2. 2018-2024年司美格鲁肽销售额详情，来源：药渡数据-全球药物库Orforglipron的核心竞争力在于其给药便利性、生产成本优势以及不逊于注射剂的疗效。36mg剂量组的A1C降幅（1.5%）与司美格鲁肽（治疗30周后为1.4%-1.6%）相当。此外，小分子药物的合成难度低于多肽类注射剂，礼来预计能够实现“全球充足供应”。然而，Orforglipron也面临潜在挑战。口服药物的吸收可能受到个体差异的影响，尽管礼来通过制剂优化提升了稳定性，但个体间血药浓度差异仍需长期监测。此外，诺和诺德的口服司美格鲁肽（Rybelsus）已上市，但需空腹服用且疗效略逊于注射剂。Orforglipron若获批，可能会直接冲击其市场份额。PART.03GLP-1赛道进入“双雄争霸”时代据摩根大通预测，2030年全球GLP-1类药物市场规模将达1000亿美元，其中口服剂型占比有望持续增长。如果Orforglipron于2026年获批糖尿病与肥胖适应症，将成为礼来继替尔泊肽后的又一重磅产品，预计峰值销售额可达150亿美元。Orforglipron的市场成功也将带动产业链共振。在小分子合成环节，其核心中间体需求激增，九洲药业、药明康德等企业有望受益。同时，礼来加速推进7项III期研究，泰格医药、凯莱英等临床CRO企业的订单量也随之攀升。然而，患者可及性与支付问题仍然是关键挑战。参考替尔泊肽（美国年费用约四五千美元），Orforglipron可能定价相近，但生产成本的下降或许为医保谈判提供了空间。如果无法纳入医保，自费门槛仍将限制中低收入患者使用，普惠医疗的争议也将持续存在。PART.04未来展望：GLP-1药物的“无限可能”Orforglipron的成功只是GLP-1药物创新的一个开始。礼来已启动Orforglipron用于阻塞性睡眠呼吸暂停、高血压等合并症的III期研究，未来可能覆盖心血管保护、NASH（非酒精性脂肪性肝炎）等领域。此外辉瑞、罗氏等跨国药企也在加码小分子GLP-1研发，行业进入“技术军备竞赛”。在中国市场，本土研发也在积极跟进。恒瑞医药、华东医药等企业布局口服GLP-1药物，但进度落后礼来2-3年。然而，中国原料药企业凭借成本与技术优势，可能成为Orforglipron全球供应的关键环节。结语Orforglipron的III期成功不仅是礼来的胜利，更是整个GLP-1赛道的里程碑。随着口服剂型突破技术瓶颈，糖尿病与肥胖症的治疗将从“被动注射”转向“主动管理”，患者生活质量有望大幅提升。然而，如何在疗效、安全性与可及性之间找到平衡，仍是药企、监管机构与支付方共同面临的挑战。未来十年，GLP-1赛道的创新浪潮或将催生更多颠覆性疗法，最终实现“让慢性病可控可治”的愿景。参考资料：礼来公司官方公告、美国糖尿病协会（ADA）、高盛研报、ClinicalTrials.gov*声明：本文仅是介绍医药疾病领域研究进展或简述研究概况或分享医药相关讯息，并非也不会进行治疗或诊断方案推荐，也不对相关投资构成任何建议。内容如有疏漏，欢迎沟通指出！国内男性也能打九价了！默沙东九价HPV疫苗在华获批男性适应证盘中大涨130%！映恩生物港股上市迎开门红全球药企管线资产排行榜T0P25，恒瑞、石药、百济上榜！

临床3期临床结果抗体药物偶联物

2025-04-08

·drugs

Semaglutide Ups Risk for Nonarteritic Anterior Ischemic Optic Neuropathy in Diabetes

TUESDAY, April 8, 2025 -- For patients with diabetes , semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic neuropathy (NAION), according to a study published online March 27 in JAMA Ophthalmology . Alan Y. Hsu, M.D., from the China Medical University Hospital in Taichung City, Taiwan, and colleagues conducted a cohort study to examine the association between semaglutide use and risk for NAION among patients with diabetes. The semaglutide cohort was compared to a control group of randomly selected patients with diabetes who were prescribed non-glucagon-like peptide 1 (non-GLP-1) receptor agonist (RA) medications (174,584 patients in each group). The researchers found that patients with diabetes taking semaglutide had an absence of NAION risk at the one-month, three-month, six-month, and one-year time points after the index date. However, at the two-year, three-year, and four-year time points from the index date, those taking semaglutide had an increased risk for NAION (hazard ratios, 2.39, 2.44, and 2.05, respectively). Patients with diabetes and concomitant hypertension who were taking semaglutide had an increased risk for NAION (hazard ratio, 2.42). Patients with diabetes who had a history of Ozempic use or stand-alone Ozempic prescription history also had increased NAION risk. "Among patients with diabetes, an elevated risk of NAION was associated with semaglutide use compared with non-GLP-1 RA use," the authors write. "However, the study's retrospective design can only infer associations rather than establish causality."

临床结果

100 项与司美格鲁肽（石药集团中奇制药）相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肥胖	临床3期	中国	北京抗创联生物制药技术研究有限公司	2024-09-19
肥胖	临床3期	中国	石药集团中奇制药技术（石家庄）有限公司	2024-09-19
2型糖尿病	临床3期	中国	石药集团中奇制药技术（石家庄）有限公司	2024-02-23
2型糖尿病	临床3期	中国	北京抗创联生物制药技术研究有限公司	2024-02-23